Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine
pCR: hormone receptor‐negative · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pCR: hormone receptor‐negative compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyOR 1.28 [0.61, 2.66]4 studies · 646 participantsModerate